Literature DB >> 21831158

B-cell-dependent memory T cells impede nonmyeloablative mixed chimerism induction in presensitized mice.

V Levesque1, P D Bardwell, I Shimizu, F Haspot, G Benichou, B Y Yeap, M Sykes.   

Abstract

Presensitization to HLA antigens limits the success of organ transplantation. The achievement of donor-specific tolerance via mixed chimerism could improve outcomes of transplantation in presensitized patients. In presensitized B-cell-deficient μMT B6 mice, we developed nonmyeloablative bone marrow transplantation (BMT) regimens that successfully tolerized presensitized T cells, achieving long-term (LT) multilineage chimerism and tolerance to donor-type skin. To apply these regimens in wild-type (WT) animals while avoiding antibody-mediated destruction of donor bone marrow cells, presensitized WT B6 mice were rested >2 years to allow alloantibody clearance. However, chimerism and tolerance were not reliably achieved in LT presensitized WT B6 mice in which alloantibody had declined to minimal or undetectable levels before BMT. Strong antidonor memory T-cell responses were detected in LT presensitized WT B6 mice after rejection of donor bone marrow (BM) occurred, whereas levels of alloantibody remained consistently low. In contrast, presensitized μMT B6 mice had diminished memory T-cell responses compared to WT B6 mice. These data implicate T-cell memory, but not alloantibody, in rejection of donor BM in LT presensitized WT mice. ©2011 The Authors Journal compilation
© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831158      PMCID: PMC3816363          DOI: 10.1111/j.1600-6143.2011.03683.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  27 in total

1.  Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance.

Authors:  T Wekerle; M H Sayegh; H Ito; J Hill; A Chandraker; D A Pearson; K G Swenson; G Zhao; M Sykes
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

2.  CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway.

Authors:  H Ito; J Kurtz; J Shaffer; M Sykes
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

3.  The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo.

Authors:  Xueli Yuan; Alan D Salama; Victor Dong; Isabela Schmitt; Nader Najafian; Anil Chandraker; Hisaya Akiba; Hideo Yagita; Mohamed H Sayegh
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

4.  Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.

Authors:  Yuan Zhai; Lingzhong Meng; Feng Gao; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  Engraftment of allogeneic bone marrow following administration of anti-T cell monoclonal antibodies and low-dose irradiation.

Authors:  Y Sharabi; D H Sachs
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

6.  Dissociation of hemopoietic chimerism and allograft tolerance after allogeneic bone marrow transplantation.

Authors:  A Umemura; H Morita; X C Li; S Tahan; A P Monaco; T Maki
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

Review 7.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

8.  In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy.

Authors:  Yifa Chen; Peter S Heeger; Anna Valujskikh
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

Authors:  Dimitrios T Boumpas; Richard Furie; Susan Manzi; Gabor G Illei; Daniel J Wallace; James E Balow; Akshay Vaishnaw
Journal:  Arthritis Rheum       Date:  2003-03

10.  Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.

Authors:  Y Sharabi; D H Sachs
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

View more
  5 in total

1.  Tolerance of Lung Allografts Achieved in Nonhuman Primates via Mixed Hematopoietic Chimerism.

Authors:  M Tonsho; S Lee; A Aoyama; S Boskovic; O Nadazdin; K Capetta; R-N Smith; R B Colvin; D H Sachs; A B Cosimi; T Kawai; J C Madsen; G Benichou; J S Allan
Journal:  Am J Transplant       Date:  2015-04-22       Impact factor: 8.086

Review 2.  Mechanisms of Mixed Chimerism-Based Transplant Tolerance.

Authors:  Julien Zuber; Megan Sykes
Journal:  Trends Immunol       Date:  2017-08-18       Impact factor: 16.687

3.  Contrasting effects of B cell depletion on CD4+ and CD8+ memory T cell responses generated after transplantation.

Authors:  Jose Marino; Bruno Gonzalez-Nolasco; Xianding Wang; William Orent; Gilles Benichou
Journal:  Am J Transplant       Date:  2020-05-04       Impact factor: 8.086

4.  Macrochimerism in Intestinal Transplantation: Association With Lower Rejection Rates and Multivisceral Transplants, Without GVHD.

Authors:  J Zuber; S Rosen; B Shonts; B Sprangers; T M Savage; S Richman; S Yang; S P Lau; S DeWolf; D Farber; G Vlad; E Zorn; W Wong; J Emond; B Levin; M Martinez; T Kato; M Sykes
Journal:  Am J Transplant       Date:  2015-05-18       Impact factor: 8.086

Review 5.  Desensitization for solid organ and hematopoietic stem cell transplantation.

Authors:  Andrea A Zachary; Mary S Leffell
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.